Aprea Therapeutics, Inc. (APRE) · Nov 20, 2026 · Other events

Aprea clinical data add durable APR-1051 response, but sample stays early

Above the bar — 1 confirmed PR >10 months; 1 unconfirmed PR; 5 stable disease >4 months

Aprea’s clinical data update adds a 10-month confirmed response and target engagement, but APR-1051 remains an early, small Phase 1 story.

Aprea is narrowing its lead program around biomarker-selected cancers. APR-1051 is still an early Phase 1 WEE1-inhibitor program, but the company has shifted from broad dose escalation toward focused cohorts in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer after earlier signs of activity. The Q4 2026 data update itself was already expected, so the event is partly anticipated rather than a surprise.

The clinical signal has strengthened modestly, mainly through durability. In 56 treated patients, Aprea reports one confirmed partial response lasting more than 10 months at the cutoff, a second unconfirmed partial response, and five patients with stable disease lasting more than four months. This is better than a merely anecdotal single response because it adds follow-up and another response, but it remains too small and immature to establish response rates or a recommended Phase 2 dose.

The biology and dosing story are supportive, not yet decisive. Pharmacodynamic evidence shows that APR-1051 is engaging its WEE1 target across multiple dose levels, while the company says the safety profile and pharmacokinetics support continuous once-daily dosing. 〔0〕 That helps validate the development plan, but the study is still primarily designed to determine safety, dose limits, and the recommended Phase 2 dose.

The next value-creating step is a more selective expansion, not an immediate efficacy readout. Aprea is adding sites, developing an IHC assay for cyclin E, and plans to enroll at least 50 patients in uterine serous carcinoma or cyclin E-overexpressing platinum-resistant ovarian cancer. Completion of dose escalation and backfill expansion is expected in the second quarter of 2027. 〔1〕

Bottom line: This update clears the early clinical bar by adding durability, another response, and target engagement. It improves confidence in APR-1051’s direction, but the program remains an early Phase 1 story that still needs a larger biomarker-selected dataset and dose selection.

What to watch next

Dose escalation and backfill expansion enrollment, Q2 2027

Original filing on SEC EDGAR

Aprea clinical data add durable APR-1051 response, but sample stays early | APRE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.